Although this study highlighted metabolic alterations that lead to variance in 5-ALA-mediated fluorescence in IDH-mutated glioma cells, it is still not clear how IDH mutations influence glioma tissue fluorescence following 5-ALA treatment in the clinical setting. The gene discussed is IDH1; the disease is glioma.